High-volume energy drinks · Original findings did not support the no-QTc/blood-pressure-problem claim

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Biomarkers · No-effect claim · HarmsWhat is the original direction of the selected existing question?Required	The selected question is “No QTc or blood-pressure effect” in the existing subclaim, distinguished from its verdict record. The original no-problem claim wording is retained, separately from the original context that harm signals did not support it. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new independent-claim certification, invented verdict or subclaim subdivision was made.	Exact subclaim wording, Korean/English text and question/record relationship	If the question changes, retain the original existing wording, previous complete version and change event separately.
2	Partly verified	Full text not readStored summary read	N02 · Biomarkers · No-effect claim · HarmsHow do the subclaim verdict and parent score/axes differ?Required	The subclaim is D, with the note “QTc and blood-pressure trajectories differed from placebo.” It has no score/status/axes fields. Parent D30, Caution and B/S/R1/I2/E-/B2/C0 are parent context. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Subclaim score/status/assessment axes are null; parent values are not inserted.	Actual subclaim grade/note, absent score/status/axes and parent D30	When evidence is updated, distinguish original value preservation from actual judgment events.
3	Partly verified	Full text not readStored summary read	N03 · Biomarkers · No-effect claim · HarmsWhat are the actual trial population and applicability boundaries?Required	The 2019 trial involved 34 healthy adults aged 18–40 without cardiovascular disease, hypertension, QT prolongation or regular medication use. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.	Healthy adults aged 18–40, baseline exclusions and selected population	Distinguish other population materials by baseline risk, medication, age and actual eligibility.
4	Partly verified	Full text not readStored summary read	N04 · Biomarkers · No-effect claim · HarmsWhat are the actual identity and duration of the research exposure?Required	The original exposure was a single intake of 946 mL of energy drink containing about 300–320 mg caffeine within one hour. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.	946 mL, about 300–320 mg caffeine and one exposure within one hour	Connect nominal/actual and product-specific exposure differences with the relevant outcome.
5	Partly verified	Full text not readStored summary read	N05 · Biomarkers · No-effect claim · HarmsWhat are the identity and composition differences of drinks A/B and placebo?Required	The stored review summary records investigators preparing commercial drinks in identical containers and participants consuming A, B and placebo separately. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.	Commercial products A/B, preparation in identical containers and placebo composition	If actual product materials are provided, distinguish caffeine, combined ingredients and placebo differences.
6	Partly verified	Full text not readStored summary read	N06 · Biomarkers · No-effect claim · HarmsHow do 240-minute measurements differ from long-term observation?Required	The 2019 trial measured QTc and blood pressure every 30 minutes through 240 minutes after a single exposure. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.	Measurements through 240 minutes, 30-minute intervals and acute time points	Distinguish actual observation durations of acute biomarkers and long-term clinical outcomes in follow-up materials.
7	Partly verified	Full text not readStored summary read	N07 · Biomarkers · No-effect claim · HarmsWhat are the sequence and analysis units of the crossover trial?Required	The recorded design is a randomized double-masked placebo-controlled crossover trial; the same participants underwent each drink condition. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.	A/B/placebo in the same 34 people, sequence allocation and carryover/period effects	When materials are supplemented, distinguish conditions/time points within the same person and crossover assumptions.
8	Unverified	Full text not readStored summary read	N08 · Biomarkers · No-effect claim · HarmsWhat are the common conditions and other exposures?Required	The stored review summary preserves a healthy population and acute comparison of three drinks. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.	Pre-visit caffeine/activity, meals, medication and measurement environment	Record actual common product-comparison conditions and other exposures together in follow-up materials.
9	Partly verified	Full text not readStored summary read	N09 · Biomarkers · No-effect claim · HarmsHow were double masking, measurement and interpretation implemented?Required	The original design is described as double-masked, with investigators preparing drinks in identical containers. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.	Roles masked, identical containers and ECG/blood-pressure collection	Connect actual masking by role and measurement processes to outcomes.
10	Partly verified	Full text not readStored summary read	N10 · Biomarkers · No-effect claim · HarmsWhat are the registration identifier and current registration-content status?Required	NCT03196908 appears in the first existing evidence record and research description. The 2017 citation has no separate registration identifier. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.	2019 NCT03196908 and registration history/plans	If registration materials are provided, distinguish the report, plans and actual reading scope.
11	Partly verified	Full text not readStored summary read	N11 · Biomarkers · No-effect claim · HarmsWhat are the bibliographies and source locations of the two reports?Required	R01 is Shah SA et al., 2019, J Am Heart Assoc 8:e011318, PMID 31137991. R02 is Fletcher EA et al., 2017, the same journal 6:e004448, PMID 28446495. There is one evidence group and two citations. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.	Shah 2019, Fletcher 2017, PMIDs and evidence/citations	When bibliography is supplemented, distinguish report identity, original results and change events.
12	Partly verified	Full text not readStored summary read	N12 · Biomarkers · No-effect claim · HarmsWhat is the scope of investigator overlap and Mayo blood-pressure replication?Required	The stored review summary states that 2017 involved overlapping investigators and was not independent replication; independent Mayo investigators replicated blood pressure only. Limited independent QTc replication is a historical description. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.	Identical/unknown cohorts, author overlap and independent QTc/BP distinction	Distinguish identical cohorts, investigator overlap, independent institutions and QTc/blood-pressure endpoint replication in new materials.
13	Partly verified	Full text not readStored summary read	N13 · Biomarkers · No-effect claim · HarmsWhat is the original scope of support and disclosed relationships?Required	The original record states University of the Pacific support, no reported energy-drink-company funding and Sachin A. Shah’s expert-witness history in caffeine energy-drink litigation. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.	2019 university support, unreported company funding and litigation expert-witness history	If disclosures are provided, distinguish reports, support types, external relationships and historical/current scope.
14	Partly verified	Full text not readStored summary read	N14 · Biomarkers · No-effect claim · HarmsHow are original dates, Korean/English text, corrections, axes and history retained?Required	The reference date is 2026-08-26, corrections are an empty array and deliberation an empty string. Complete stored review text preserves Korean/English content, synthesized summaries, verdict decisions, assessment axes and false flags. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.	2026-08-26, empty corrections/deliberation and parent/sibling context	If changed materials arise, distinguish the complete pre-change original, events, versions and separate application.
15	Partly verified	Full text not readStored summary read	N15 · Biomarkers · No-effect claim · HarmsWhich materials were actually read?Required	The complete preserved 2961 JSON and its two existing selections were read for preparation. Reading of each report’s summary is distinguished from unread external originals in each checklist. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.	Complete local JSON summary, report-specific material items and unread external originals	Distinguish public availability, access, acquisition, actual reading scope and dates for new materials.
16	Partly verified	Full text not readStored summary read	N16 · Biomarkers · No-effect claim · HarmsAre two checklists/material items distinguished from trials/participants?Required	The two existing questions have different scopes in the same complete stored summary. Connecting R01’s 34 people, A/B/placebo and time-point materials to both checklists creates no new participant or replication trial. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.	s0/s1, two reports, conditions/time points and null unique trial/participant totals	Connect additional reports by distinguishing identical/different populations, institutions and endpoints.
17	Partly verified	Full text not readStored summary read	N17 · Biomarkers · No-effect claim · HarmsWhat is connected when new materials become available?Required	The two existing questions are prepared separately in the same seven-column format. Each condition was saved/frozen first, with a separate application timestamp retained. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.	Conditions, originals, observations, corrections, reading and change events	Separate actual additions/changes into complete prior originals, events, condition versions/freezing, separate application and current handoff.
18	Partly verified	Full text not readStored summary read	N18 · Biomarkers · No-effect claim · HarmsWhat are the QTc correction methods and actual endpoints?Required	The existing evidence endpoint is Bazett- and Fridericia-corrected QTc; the numeric table concerns maximum Bazett-QTc change. QTc is an ECG marker of delayed ventricular repolarization. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Correction formulas, original QT/RR, equipment/interpretation, Fridericia values and actual maximum derivation are unverified.	Bazett/Fridericia, maximum change and QTc definition	If materials are provided, connect correction methods, original values/changes, time points and maxima separately.
19	Partly verified	Full text not readStored summary read	N19 · Biomarkers · No-effect claim · HarmsHow are original maximum Bazett-QTc values retained?Required	Maximum Bazett-QTc changes are A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms. Each is recorded as a maximum change from baseline. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. The statistical definition of ±, condition-specific n, maximum time points, baseline values and original change variance tables are unverified.	A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms	Connect condition-specific values and actual statistical definitions in new tables.
20	Partly verified	Full text not readStored summary read	N20 · Biomarkers · No-effect claim · HarmsWhat are the actual comparisons in overall and pairwise tests?Required	The original reader answer records overall P=.005, A versus placebo P=.04 and B versus placebo P<.01; both drinks had larger maximum QTc changes than placebo. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Test models, multiplicity corrections, estimated between-condition differences and paired analysis details are unverified.	Overall P=.005, A versus placebo P=.04 and B versus placebo P<.01	Connect overall, pairwise and adjusted tests with the relevant outcomes in analysis materials.
21	Partly verified	Full text not readStored summary read	N21 · Biomarkers · No-effect claim · HarmsHow do QTc-by-time results differ from maximum-change tests?Required	QTc-by-time interaction P<.001 and overall maximum Bazett-QTc test P=.005 are separate results in the original stored review summary. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Correction-specific time models, between-condition effects/intervals at each time point and measurement denominators are unverified.	Time interaction P<.001 and overall maximum P=.005	When materials are supplemented, distinguish time interactions from contrasts of a single summary value.
22	Partly verified	Full text not readStored summary read	N22 · Biomarkers · No-effect claim · HarmsWhich sites and pressure types do blood-pressure results concern?Required	The original research description states that peripheral and central systolic- and diastolic-pressure-by-time interactions were all P<.001. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Absolute values, changes, between-group differences, mmHg intervals and visit-specific measurement/denominators for each pressure are absent from the stored review summary.	Peripheral/central, systolic/diastolic and time interactions	Distinguish sites, pressure types, time points and within-/between-condition results in new blood-pressure materials.
23	Partly verified	Full text not readStored summary read	N23 · Biomarkers · No-effect claim · HarmsWhat is the scope of unreported between-condition 95% CIs?Required	Original research text and synthesized summaries record that the paper did not present between-condition 95% CIs. External originals/supplementary tables were not read this time. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual intervals/non-reporting across current external materials and effect denominators are unverified.	Between-condition intervals, ± notation, P values and original non-reporting record	Connect provided intervals with actual correction methods, measures and denominators.
24	Partly verified	Full text not readStored summary read	N24 · Biomarkers · No-effect claim · HarmsWhat kind of threshold is 10 ms?Required	Sample size assumed detection of a 10-ms QTc mean difference. The stored review summary states that without a CI for a between-condition difference exceeding 10 ms, this was not used to exclude a clinical threshold. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Validated clinical importance, the relevant between-condition interval and prespecified criterion details are unverified.	Power assumption of a 10-ms QTc mean difference and clinical interpretation boundary	If materials are provided, connect sample-size assumptions and validated clinical thresholds separately.
25	Partly verified	Full text not readStored summary read	N25 · Biomarkers · No-effect claim · HarmsWhat are the 34-person sample, actual outcome analysis and missingness?Required	The stored review summary’s n is 34 healthy adults. Details are insufficient to establish 34 effective measurements/analyses in every crossover condition/time point. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Allocation/exposure/condition completion, effective ECG/blood-pressure n, missingness reasons/handling and analysis populations/models are unverified.	34 study participants, effective n by condition/time, completion and ITT/paired analysis	If original tables are provided, distinguish person, condition, time-point and outcome denominators.
26	Partly verified	Full text not readStored summary read	N26 · Biomarkers · No-effect claim · HarmsWhat are the prespecified primary QTc and blood-pressure hierarchy?Required	The stored review summary records worsening of prespecified primary QTc. Blood-pressure time interactions are also recorded, but separate hierarchy/plan details are absent. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Original registration/SAP QTc definitions, correction methods, maximum/time analyses, primary/secondary blood pressure and multiple testing are unverified.	Prespecified QTc, correction/maxima/time analyses and blood-pressure hierarchy	If plans are provided, connect actual prespecified/post hoc distinctions, endpoint hierarchy and selected analyses.
27	Partly verified	Full text not readStored summary read	N27 · Biomarkers · No-effect claim · HarmsHow are the no-problem claim and original observed direction distinguished?Required	The exact question is “No QTc or blood-pressure effect.” The stored review summary records that QTc/blood-pressure trajectory differences from placebo did not support the claim. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Clinical importance of measured differences and applicability to persistence/long-term/all exposures are unverified.	No-effect claim, QTc/blood-pressure changes and original D/note	Connect original claim, observed direction and verdict context as recorded; distinguish separate actual clinical outcomes.
28	Partly verified	Full text not readStored summary read	N28 · Biomarkers · No-effect claim · HarmsWhat is the boundary between surrogate markers and clinical events?Required	The stored review summary explicitly states that this is a four-hour biomarker trial that did not test arrhythmia, hospitalization or death. The sibling s1 grade is ?. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct clinical event definitions, event counts, denominators, durations and effect intervals are unverified in these materials.	QTc/blood-pressure surrogate signals and direct arrhythmia/hospitalization/death outcomes	Retain a proposal to report clinical-event materials with definitions, verification, risk periods and denominators separate from biomarkers.
29	Partly verified	Full text not readStored summary read	N29 · Biomarkers · No-effect claim · HarmsIs this extended to other doses, chronic use or populations?Required	The stored review summary states that results cannot be extended to chronic intake, one can or less, adolescents, cardiovascular patients or medication users. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct QTc/blood-pressure/clinical-event materials for other products/doses, repeated exposure and at-risk populations are unverified.	Healthy adults aged 18–40, a single high-volume exposure and direct evidence for other conditions	If direct materials are provided, distinguish exposure/population/duration differences for the relevant question.
30	Partly verified	Full text not readStored summary read	N30 · Biomarkers · No-effect claim · HarmsWhat is the scope of the earlier 2017 report and Mayo blood-pressure context?Required	Fletcher 2017 has a bibliography for an energy-drink-versus-caffeine ECG/hemodynamic trial and a summary of QTc prolongation direction. Independent Mayo blood-pressure descriptions are historical context without a bibliography. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual 2017 effects/CIs/sample, Mayo bibliography/conditions/values and direct independent QTc verification are unverified.	Overlapping-investigator QTc direction and independent blood-pressure-only description	Distinguish institution/population relationships and actual replicated endpoints in additional report materials.
31	Partly verified	Full text not readStored summary read	H01 · Biomarkers · No-effect claim · HarmsAre biomarkers, harms and clinical-event collection distinguished?Supporting harm information	Original materials record QTc/BP time changes and no testing of arrhythmia/hospitalization/death. The original context is that biomarker differences did not support the selected no-problem claim. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.	QTc/BP testing, verified clinical events and adverse-event definitions	Retain a proposal to distinguish measured biomarkers, symptoms and verified events in follow-up materials.
32	Partly verified	Full text not readStored summary read	H02 · Biomarkers · No-effect claim · HarmsWhat are harm timing and actual exposure?Supporting harm information	Research exposure was 946 mL with about 300–320 mg caffeine within one hour; measurements covered 240 minutes. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.	Single research exposure, acute measurement and event-risk periods	Retain a proposal to distinguish exposure, testing times and clinical-event risk periods in harm materials.
33	Partly verified	Full text not readStored summary read	H03 · Biomarkers · No-effect claim · HarmsHow do between-condition biomarker differences differ from clinical harm comparisons?Supporting harm information	The stored review summary records maximum QTc and blood-pressure time differences, while direct clinical arrhythmia/hospitalization/death comparisons were not tested. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.	Biomarker outcomes for A/B/placebo and clinical-event comparisons	Retain a proposal to connect direct harm materials using event definitions, comparisons and intervals separate from biomarkers.
34	Partly verified	Full text not readStored summary read	H04 · Biomarkers · No-effect claim · HarmsWhat are safety and event denominators?Supporting harm information	The 34 people in the stored review summary are healthy adult crossover-trial participants; separate denominators for each event/safety analysis were not provided. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.	34 people and actual denominators by condition/time/event	Retain a proposal to distinguish person, condition, time-point and measurement/event denominators in originals.
35	Partly verified	Full text not readStored summary read	H05 · Biomarkers · No-effect claim · HarmsWhat are alternative harm factors and ingredient-specific attribution?Supporting harm information	Exposure was commercial energy drink with about 300–320 mg caffeine. The stored review summary preserves a whole-product comparison. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.	Caffeine, combined ingredients, baseline/concurrent exposures and relatedness	Retain a proposal to distinguish whole products, ingredient-specific attribution and alternative factors in direct harm materials.
36	Unverified	Full text not readStored summary read	H06 · Biomarkers · No-effect claim · HarmsAre unread, untested, unreported and zero events distinguished?Supporting harm information	Actual reading this time concerns preserved JSON summaries; the original description of untested clinical events is retained. R01 R02	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.	Actual reading level, untested clinical endpoints and original reports	Only for provided materials, connect actual zero events, missingness, non-reporting and non-collection with locations/durations.
37	Partly verified	Full text not readStored summary read	H07 · Biomarkers · No-effect claim · HarmsAre harms across reports, conditions and two checklists protected from duplicate counting?Supporting harm information	Two checklists prepare different existing questions from the same stored 2961 summary. The 2017/2019 bibliographies involve overlapping investigators; actual participant overlap is unverified. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.	2017/2019, author overlap, conditions/time points and two questions in the same summary	Retain a proposal to distinguish repeated reports of the same event from different populations/new events in harm materials.
38	Partly verified	Full text not readStored summary read	H08 · Biomarkers · No-effect claim · HarmsWhat are safety gaps for long-term use and vulnerable populations?Supporting harm information	The parent emphasizes a single high-volume exposure in healthy young adults; the original safety status is Caution. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.	Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents	Retain a proposal to record direct materials together with actual exposure, population and observation duration.
39	Partly verified	Full text not readStored summary read	H09 · Biomarkers · No-effect claim · HarmsAre signals distinguished from direct causal or clinical confirmation?Supporting harm information	Original s0 is D for the no-QTc/BP-effect claim; s1 is ? for increased clinical arrhythmia. Biomarker signals and the gap in direct clinical events are retained separately. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.	Biomarker signals, original D, direct clinical ? and unverified information	Retain a proposal to distinguish observation, relatedness, direct clinical-effect levels and change events in additional materials.

No items match your search or filter.

39 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: 2019 biomarker trial: 34 healthy adults aged 18–40 without cardiovascular disease, hypertension, QT prolongation or regular medication use. Direct clinical-event populations/denominators are unverified.
Ingredient, formulation and route: Single intake within one hour of 946 mL of energy drink containing about 300–320 mg caffeine
Dose: Original research exposure: 946 mL, about 300–320 mg caffeine, one exposure within one hour. Actual composition/intake completion and long-term exposure are unverified; this is not dosing guidance.
Comparator: 2019 within-person crossover of commercial drinks A/B versus placebo. Placebo composition/caffeine, effective n by condition and model details are unverified. The 2017 energy-drink-versus-caffeine comparison is a separate qualitative bibliography.
Measured outcome: Maximum Bazett-QTc changes: A +17.9±13.9 ms, B +19.6±15.8 ms, placebo +11.9±11.1 ms; overall P=.005, A versus placebo P=.04, B versus placebo P<.01. QTc and peripheral/central SBP/DBP-by-time interactions were all P<.001. Actual between-condition effects/CIs and quantitative blood-pressure results are unverified.
Duration: 2019 measurements every 30 minutes through 240 minutes after intake. Crossover visits/washout and actual clinical-event/long-term-risk observation are unverified.
Questions outside this scope: Transferring QTc/blood-pressure biomarker changes to occurrence of clinical arrhythmia, hospitalization or death; Converting/calculating condition-specific QTc maxima into between-group differences or ± into CIs; Creating new blood-pressure quantities, clusters/conditions/denominators or zero clinical events; Interpreting the 10-ms power assumption as a clinical-arrhythmia threshold/effect; Copying 2019 n/effects/NCT/support disclosures to 2017/Mayo; Certifying author overlap as an identical cohort or earlier/blood-pressure descriptions as independent clinical-event replication; Summing participants/trials across two checklists, reports, conditions or time points; Creating long-term/small-dose/adolescent/disease-medication population benefits/harms or intake/prevention/treatment procedures

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Shah SA, et al. Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial. J Am Heart Assoc. 2019;8:e011318. PMID: 31137991.

PubMed

Material type: 2019 energy-drink A/B versus placebo biomarker crossover trial
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Maximum Bazett-QTc changes: A +17.9±13.9 ms, B +19.6±15.8 ms, placebo +11.9±11.1 ms; overall P=.005; blood-pressure time interactions are separate. The original boundary states that direct clinical arrhythmia, hospitalization and death were not tested.
Record level: First existing evidence record / Parent QTc and blood-pressure biomarker outcomes
Study overlap and independent replication: Shah 2019 pivotal direct biomarker trial and Fletcher 2017 earlier report with overlapping investigators. Actual participant/registration relationships are unverified; an identical cohort is not established. Mayo blood-pressure replication is qualitative stored-summary context without a bibliography; no R03 is created. Two checklists/conditions/time points are not summed.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Locally preserved summary	Local copy acquired	Summary read	The relevant bibliography, results and scope in the complete stored summary were read for preparation; this is not external full-text reading.
External abstract	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the citation URL in the review summary is connected; no current abstract/access verification was made.
External full text	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the existing bibliographic link is connected; current full-text location, public availability and access are unverified.
Registration	Current publication and access unverified	Access not attempted; not acquired	Not read	Original NCT03196908 identity; content/history are currently unread.
Protocol	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item; file existence/public availability, definitions, hierarchy and dates are unverified.
Statistical analysis plan	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for crossover/conditions/time/missingness, contrasts and clinical collection scope.
Results, denominator and harm details	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for biomarkers, effective n by condition, intervals and direct clinical-endpoint collection; unread materials are not changed to zero events.
Support and interests	Current publication and access unverified	Access not attempted; not acquired	Not read	Report-specific support/roles/current relationships are unread; 2019 support descriptions are not copied as individual 2017 disclosures.

R02 · Fletcher EA, et al. Randomized Controlled Trial of High-Volume Energy Drink Versus Caffeine Consumption on ECG and Hemodynamic Parameters. J Am Heart Assoc. 2017;6:e004448. PMID: 28446495.

PubMed

Material type: Earlier 2017 energy-drink-versus-caffeine report with overlapping investigators
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: The earlier 2017 trial with overlapping investigators has only energy-drink-versus-caffeine bibliography and a summary of QTc prolongation direction. Sample, values, registration and clinical-event collection are unverified.
Record level: Second report in the existing citations · Qualitative context of the parent counterview
Study overlap and independent replication: Shah 2019 pivotal direct biomarker trial and Fletcher 2017 earlier report with overlapping investigators. Actual participant/registration relationships are unverified; an identical cohort is not established. Mayo blood-pressure replication is qualitative stored-summary context without a bibliography; no R03 is created. Two checklists/conditions/time points are not summed.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Locally preserved summary	Local copy acquired	Summary read	The relevant bibliography, results and scope in the complete stored summary were read for preparation; this is not external full-text reading.
External abstract	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the citation URL in the review summary is connected; no current abstract/access verification was made.
External full text	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the existing bibliographic link is connected; current full-text location, public availability and access are unverified.
Registration	Current publication and access unverified	Access not attempted; not acquired	Not read	2017 registration identifier is absent from the review summary; the 2019 identifier is not copied.
Protocol	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item; file existence/public availability, definitions, hierarchy and dates are unverified.
Statistical analysis plan	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for crossover/conditions/time/missingness, contrasts and clinical collection scope.
Results, denominator and harm details	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for biomarkers, effective n by condition, intervals and direct clinical-endpoint collection; unread materials are not changed to zero events.
Support and interests	Current publication and access unverified	Access not attempted; not acquired	Not read	Report-specific support/roles/current relationships are unread; 2019 support descriptions are not copied as individual 2017 disclosures.

Report counts versus independent study counts

Shah 2019 pivotal direct biomarker trial and Fletcher 2017 earlier report with overlapping investigators. Actual participant/registration relationships are unverified; an identical cohort is not established. Mayo blood-pressure replication is qualitative stored-summary context without a bibliography; no R03 is created. Two checklists/conditions/time points are not summed.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What is the original direction of the selected existing question?

Required materials and conditions: Exact subclaim wording, Korean/English text and question/record relationship
Conditions for verification: Connect Exact subclaim wording, Korean/English text and question/record relationship to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not count trials, participants or clinical events twice because two existing checklists were prepared.
Why this condition is needed: Preparation condition retaining the original scope of Exact subclaim wording, Korean/English text and question/record relationship.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are our own design

N02 · How do the subclaim verdict and parent score/axes differ?

Required materials and conditions: Actual subclaim grade/note, absent score/status/axes and parent D30
Conditions for verification: Connect Actual subclaim grade/note, absent score/status/axes and parent D30 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not inherit parent D30 or historical cross-checks as a subclaim score, current content-review pass or new independence certification.
Why this condition is needed: Preparation condition retaining the original scope of Actual subclaim grade/note, absent score/status/axes and parent D30.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N03 · What are the actual trial population and applicability boundaries?

Required materials and conditions: Healthy adults aged 18–40, baseline exclusions and selected population
Conditions for verification: Connect Healthy adults aged 18–40, baseline exclusions and selected population to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not extend the healthy young population to adolescents, patients, regular medication users or all consumers.
Why this condition is needed: Preparation condition retaining the original scope of Healthy adults aged 18–40, baseline exclusions and selected population.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

N04 · What are the actual identity and duration of the research exposure?

Required materials and conditions: 946 mL, about 300–320 mg caffeine and one exposure within one hour
Conditions for verification: Connect 946 mL, about 300–320 mg caffeine and one exposure within one hour to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not calculate or create can counts, caffeine equivalents, safe limits or intake/manufacturing/dosing guidance.
Why this condition is needed: Preparation condition retaining the original scope of 946 mL, about 300–320 mg caffeine and one exposure within one hour.
Referenced methods: M03 §3.2.2–3.2.3; reverse labeling and test adaptations are Chamgap's own design

N05 · What are the identity and composition differences of drinks A/B and placebo?

Required materials and conditions: Commercial products A/B, preparation in identical containers and placebo composition
Conditions for verification: Connect Commercial products A/B, preparation in identical containers and placebo composition to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not use the 2017 caffeine-comparison title to verify that the 2019 placebo was caffeine-matched.
Why this condition is needed: Preparation condition retaining the original scope of Commercial products A/B, preparation in identical containers and placebo composition.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

N06 · How do 240-minute measurements differ from long-term observation?

Required materials and conditions: Measurements through 240 minutes, 30-minute intervals and acute time points
Conditions for verification: Connect Measurements through 240 minutes, 30-minute intervals and acute time points to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert four hours into sufficient clinical-event testing duration or long-term safety.
Why this condition is needed: Preparation condition retaining the original scope of Measurements through 240 minutes, 30-minute intervals and acute time points.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; Design-specific harm questions in M19 §19.2; Detailed temporal relationships are internally designed

N07 · What are the sequence and analysis units of the crossover trial?

Required materials and conditions: A/B/placebo in the same 34 people, sequence allocation and carryover/period effects
Conditions for verification: Connect A/B/placebo in the same 34 people, sequence allocation and carryover/period effects to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not sum A/B/placebo, repeated time points or two checklists as independent participants/trials.
Why this condition is needed: Preparation condition retaining the original scope of A/B/placebo in the same 34 people, sequence allocation and carryover/period effects.
Referenced methods: M08 §8.1–8.2.3; CHAMGAP adaptation; Distinction between studies and reports in M04 §4.6.1–4.6.2; Cohort/outcome connections are CHAMGAP adaptations

N08 · What are the common conditions and other exposures?

Required materials and conditions: Pre-visit caffeine/activity, meals, medication and measurement environment
Conditions for verification: Connect Pre-visit caffeine/activity, meals, medication and measurement environment to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not invent fasting/rest/restriction times or experimental/daily-life procedures absent from the stored review summary.
Why this condition is needed: Preparation condition retaining the original scope of Pre-visit caffeine/activity, meals, medication and measurement environment.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; Chamgap adaptation

N09 · How were double masking, measurement and interpretation implemented?

Required materials and conditions: Roles masked, identical containers and ECG/blood-pressure collection
Conditions for verification: Connect Roles masked, identical containers and ECG/blood-pressure collection to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not newly verify masking of all interpretations or absence of measurement errors solely from identical containers or a design label.
Why this condition is needed: Preparation condition retaining the original scope of Roles masked, identical containers and ECG/blood-pressure collection.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

N10 · What are the registration identifier and current registration-content status?

Required materials and conditions: 2019 NCT03196908 and registration history/plans
Conditions for verification: Connect 2019 NCT03196908 and registration history/plans to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not copy the 2019 NCT as the 2017 registration identifier or upgrade identifier presence to registration verification/link checks.
Why this condition is needed: Preparation condition retaining the original scope of 2019 NCT03196908 and registration history/plans.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a and M04 §4.6.3; Chamgap application

N11 · What are the bibliographies and source locations of the two reports?

Required materials and conditions: Shah 2019, Fletcher 2017, PMIDs and evidence/citations
Conditions for verification: Connect Shah 2019, Fletcher 2017, PMIDs and evidence/citations to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not create an evidence group absent from the stored summary for R02 or infer DOI/PMCID from article numbers.
Why this condition is needed: Preparation condition retaining the original scope of Shah 2019, Fletcher 2017, PMIDs and evidence/citations.
Referenced methods: M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

N12 · What is the scope of investigator overlap and Mayo blood-pressure replication?

Required materials and conditions: Identical/unknown cohorts, author overlap and independent QTc/BP distinction
Conditions for verification: Connect Identical/unknown cohorts, author overlap and independent QTc/BP distinction to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not equate investigator overlap with an identical cohort or create R03/independent clinical-arrhythmia evidence from unspecified Mayo mentions.
Why this condition is needed: Preparation condition retaining the original scope of Identical/unknown cohorts, author overlap and independent QTc/BP distinction.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N13 · What is the original scope of support and disclosed relationships?

Required materials and conditions: 2019 university support, unreported company funding and litigation expert-witness history
Conditions for verification: Connect 2019 university support, unreported company funding and litigation expert-witness history to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not upgrade university support or unreported company funding to new independence certification, absence of conflicts or identical 2017 support.
Why this condition is needed: Preparation condition retaining the original scope of 2019 university support, unreported company funding and litigation expert-witness history.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N14 · How are original dates, Korean/English text, corrections, axes and history retained?

Required materials and conditions: 2026-08-26, empty corrections/deliberation and parent/sibling context
Conditions for verification: Connect 2026-08-26, empty corrections/deliberation and parent/sibling context to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not fill original grades, absences, empty values or historical cross-checks with new values/current completed review.
Why this condition is needed: Preparation condition retaining the original scope of 2026-08-26, empty corrections/deliberation and parent/sibling context.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

N15 · Which materials were actually read?

Required materials and conditions: Complete local JSON summary, report-specific material items and unread external originals
Conditions for verification: Connect Complete local JSON summary, report-specific material items and unread external originals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert original citation links, historical paper descriptions or copies into external full-text reading/successful access.
Why this condition is needed: Preparation condition retaining the original scope of Complete local JSON summary, report-specific material items and unread external originals.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N16 · Are two checklists/material items distinguished from trials/participants?

Required materials and conditions: s0/s1, two reports, conditions/time points and null unique trial/participant totals
Conditions for verification: Connect s0/s1, two reports, conditions/time points and null unique trial/participant totals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not add two checklists/reports/crossover conditions or 34-person values to create an independent total sample.
Why this condition is needed: Preparation condition retaining the original scope of s0/s1, two reports, conditions/time points and null unique trial/participant totals.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; design-specific adaptation is Chamgap’s own design

N17 · What is connected when new materials become available?

Required materials and conditions: Conditions, originals, observations, corrections, reading and change events
Conditions for verification: Connect Conditions, originals, observations, corrections, reading and change events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Original candidate pending/eligibility indications are historical; do not reactivate them as active review/waiting.
Why this condition is needed: Preparation condition retaining the original scope of Conditions, originals, observations, corrections, reading and change events.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

N18 · What are the QTc correction methods and actual endpoints?

Required materials and conditions: Bazett/Fridericia, maximum change and QTc definition
Conditions for verification: Connect Bazett/Fridericia, maximum change and QTc definition to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not transfer Bazett values to Fridericia or clinical-arrhythmia outcomes.
Why this condition is needed: Preparation condition retaining the original scope of Bazett/Fridericia, maximum change and QTc definition.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

N19 · How are original maximum Bazett-QTc values retained?

Required materials and conditions: A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms
Conditions for verification: Connect A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not call these original values between-group differences or subtract placebo values to calculate new effects/CIs.
Why this condition is needed: Preparation condition retaining the original scope of A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms.
Referenced methods: M03 §3.2.4 and M15 §§15.3.1–15.3.3; question-specific outcome adaptation is Chamgap-designed; M04 §4.6.3 and M15 §§15.3.1–15.3.3; status separation is Chamgap-designed

N20 · What are the actual comparisons in overall and pairwise tests?

Required materials and conditions: Overall P=.005, A versus placebo P=.04 and B versus placebo P<.01
Conditions for verification: Connect Overall P=.005, A versus placebo P=.04 and B versus placebo P<.01 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert pairwise P values into a direct A/B superiority or clinical-risk ranking.
Why this condition is needed: Preparation condition retaining the original scope of Overall P=.005, A versus placebo P=.04 and B versus placebo P<.01.
Referenced methods: M08 §8.2.2, M15 §15.3.1; CHAMGAP adaptation; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP

N21 · How do QTc-by-time results differ from maximum-change tests?

Required materials and conditions: Time interaction P<.001 and overall maximum P=.005
Conditions for verification: Connect Time interaction P<.001 and overall maximum P=.005 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert time-interaction P values into effects at particular time points, individual conditions or clinical events.
Why this condition is needed: Preparation condition retaining the original scope of Time interaction P<.001 and overall maximum P=.005.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

N22 · Which sites and pressure types do blood-pressure results concern?

Required materials and conditions: Peripheral/central, systolic/diastolic and time interactions
Conditions for verification: Connect Peripheral/central, systolic/diastolic and time interactions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not create new values/conclusions for blood-pressure magnitude, hypertension diagnosis, sustained increases or clinical events.
Why this condition is needed: Preparation condition retaining the original scope of Peripheral/central, systolic/diastolic and time interactions.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

N23 · What is the scope of unreported between-condition 95% CIs?

Required materials and conditions: Between-condition intervals, ± notation, P values and original non-reporting record
Conditions for verification: Connect Between-condition intervals, ± notation, P values and original non-reporting record to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert ± into CIs or calculate between-condition CIs/effects from P values or sample size.
Why this condition is needed: Preparation condition retaining the original scope of Between-condition intervals, ± notation, P values and original non-reporting record.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design

N24 · What kind of threshold is 10 ms?

Required materials and conditions: Power assumption of a 10-ms QTc mean difference and clinical interpretation boundary
Conditions for verification: Connect Power assumption of a 10-ms QTc mean difference and clinical interpretation boundary to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not newly confirm a between-condition threshold or arrhythmia risk because each condition’s maximum change exceeds 10 ms.
Why this condition is needed: Preparation condition retaining the original scope of Power assumption of a 10-ms QTc mean difference and clinical interpretation boundary.
Referenced methods: M15 §§15.3.1–15.3.3; Chamgap adaptation

N25 · What are the 34-person sample, actual outcome analysis and missingness?

Required materials and conditions: 34 study participants, effective n by condition/time, completion and ITT/paired analysis
Conditions for verification: Connect 34 study participants, effective n by condition/time, completion and ITT/paired analysis to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not copy 34 as a verified analysis denominator at each time point or multiply it by observations.
Why this condition is needed: Preparation condition retaining the original scope of 34 study participants, effective n by condition/time, completion and ITT/paired analysis.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N26 · What are the prespecified primary QTc and blood-pressure hierarchy?

Required materials and conditions: Prespecified QTc, correction/maxima/time analyses and blood-pressure hierarchy
Conditions for verification: Connect Prespecified QTc, correction/maxima/time analyses and blood-pressure hierarchy to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not upgrade parent assessment axes or historical stored descriptions to current plan-review certification.
Why this condition is needed: Preparation condition retaining the original scope of Prespecified QTc, correction/maxima/time analyses and blood-pressure hierarchy.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

N27 · How are the no-problem claim and original observed direction distinguished?

Required materials and conditions: No-effect claim, QTc/blood-pressure changes and original D/note
Conditions for verification: Connect No-effect claim, QTc/blood-pressure changes and original D/note to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not reverse the original claim into confirmed increased clinical arrhythmia or make a new assessment.
Why this condition is needed: Preparation condition retaining the original scope of No-effect claim, QTc/blood-pressure changes and original D/note.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; Status distinctions are designed by CHAMGAP; Question clarification principles in M03 §3.1 and §3.2.1–3.2.4; Detailed separation rules are internally designed

N28 · What is the boundary between surrogate markers and clinical events?

Required materials and conditions: QTc/blood-pressure surrogate signals and direct arrhythmia/hospitalization/death outcomes
Conditions for verification: Connect QTc/blood-pressure surrogate signals and direct arrhythmia/hospitalization/death outcomes to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not transfer QTc prolongation/blood-pressure differences to occurrence effects for clinical arrhythmia, hospitalization or death.
Why this condition is needed: Preparation condition retaining the original scope of QTc/blood-pressure surrogate signals and direct arrhythmia/hospitalization/death outcomes.
Referenced methods: M03 §3.2.4; internally defined extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

N29 · Is this extended to other doses, chronic use or populations?

Required materials and conditions: Healthy adults aged 18–40, a single high-volume exposure and direct evidence for other conditions
Conditions for verification: Connect Healthy adults aged 18–40, a single high-volume exposure and direct evidence for other conditions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not create small-dose safety, chronic harms, general-population intake limits or dosing/care guidance.
Why this condition is needed: Preparation condition retaining the original scope of Healthy adults aged 18–40, a single high-volume exposure and direct evidence for other conditions.
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

N30 · What is the scope of the earlier 2017 report and Mayo blood-pressure context?

Required materials and conditions: Overlapping-investigator QTc direction and independent blood-pressure-only description
Conditions for verification: Connect Overlapping-investigator QTc direction and independent blood-pressure-only description to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not copy 2019 values, n or NCT to 2017/Mayo or convert the description into independent clinical-event replication.
Why this condition is needed: Preparation condition retaining the original scope of Overlapping-investigator QTc direction and independent blood-pressure-only description.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; Status distinctions are designed by CHAMGAP; M04 §4.6.1–4.6.2, M15 §15.3.1; CHAMGAP adaptation

H01 · Are biomarkers, harms and clinical-event collection distinguished?

Required materials and conditions: QTc/BP testing, verified clinical events and adverse-event definitions
Conditions for verification: Connect QTc/BP testing, verified clinical events and adverse-event definitions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not convert biomarker worsening into clinical-event counts or untested outcomes into zero adverse events.
Why this condition is needed: Preparation condition retaining the original scope of QTc/BP testing, verified clinical events and adverse-event definitions.
Referenced methods: M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

H02 · What are harm timing and actual exposure?

Required materials and conditions: Single research exposure, acute measurement and event-risk periods
Conditions for verification: Connect Single research exposure, acute measurement and event-risk periods to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not convert the original exposure into recommended intake, a safe dose or prevention/treatment methods.
Why this condition is needed: Preparation condition retaining the original scope of Single research exposure, acute measurement and event-risk periods.
Referenced methods: M19 §19.2 design-specific harm questions; timing details are Chamgap-designed

H03 · How do between-condition biomarker differences differ from clinical harm comparisons?

Required materials and conditions: Biomarker outcomes for A/B/placebo and clinical-event comparisons
Conditions for verification: Connect Biomarker outcomes for A/B/placebo and clinical-event comparisons to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not transfer biomarker P values to clinical-harm P values or between-condition event risks.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker outcomes for A/B/placebo and clinical-event comparisons.
Referenced methods: M19 §§19.2.2–19.2.4 and M03 §3.2.3; Chamgap adaptation

H04 · What are safety and event denominators?

Required materials and conditions: 34 people and actual denominators by condition/time/event
Conditions for verification: Connect 34 people and actual denominators by condition/time/event to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not multiply crossover conditions/time measurements into participant counts or calculate risk rates from unread materials.
Why this condition is needed: Preparation condition retaining the original scope of 34 people and actual denominators by condition/time/event.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3 and M19 §§19.1.2–19.2.4; design-specific adaptation is Chamgap-designed

H05 · What are alternative harm factors and ingredient-specific attribution?

Required materials and conditions: Caffeine, combined ingredients, baseline/concurrent exposures and relatedness
Conditions for verification: Connect Caffeine, combined ingredients, baseline/concurrent exposures and relatedness to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not attribute every signal to caffeine alone or established harm from a particular ingredient, or invent mechanisms/event cases.
Why this condition is needed: Preparation condition retaining the original scope of Caffeine, combined ingredients, baseline/concurrent exposures and relatedness.
Referenced methods: M19 §§19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap-designed

H06 · Are unread, untested, unreported and zero events distinguished?

Required materials and conditions: Actual reading level, untested clinical endpoints and original reports
Conditions for verification: Connect Actual reading level, untested clinical endpoints and original reports to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not convert currently unread materials into zero side effects, failed access, an absent paper or confirmed direct clinical harm.
Why this condition is needed: Preparation condition retaining the original scope of Actual reading level, untested clinical endpoints and original reports.
Referenced methods: M19 §§19.1.2–19.2.4 and M04 §4.6.3; Chamgap adaptation

H07 · Are harms across reports, conditions and two checklists protected from duplicate counting?

Required materials and conditions: 2017/2019, author overlap, conditions/time points and two questions in the same summary
Conditions for verification: Connect 2017/2019, author overlap, conditions/time points and two questions in the same summary to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not equate investigator overlap with the same cohort or count two bibliographies/checklists as new independent-event replication.
Why this condition is needed: Preparation condition retaining the original scope of 2017/2019, author overlap, conditions/time points and two questions in the same summary.
Referenced methods: M04 §§4.6.1–4.6.2; harm-material adaptation is Chamgap-designed; M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

H08 · What are safety gaps for long-term use and vulnerable populations?

Required materials and conditions: Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents
Conditions for verification: Connect Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not create safe-dose, intake/care, arrhythmia prevention/treatment or medical-replacement procedures.
Why this condition is needed: Preparation condition retaining the original scope of Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation

H09 · Are signals distinguished from direct causal or clinical confirmation?

Required materials and conditions: Biomarker signals, original D, direct clinical ? and unverified information
Conditions for verification: Connect Biomarker signals, original D, direct clinical ? and unverified information to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not label original question wording as proven observation or combine biomarkers and clinical events into a new harm assessment.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker signals, original D, direct clinical ? and unverified information.
Referenced methods: Chamgap interpretive boundary informed by M19 principles; no formal causality tool was run

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

What the statuses mean

Met: The original content has been reviewed as meeting the conditions. This status is not used in this preparation.
Partly verified: Some information in the stored summary was linked during preparation; clinical verification or review is not complete.
Unverified: Required direct values, definitions or materials have not been established within the current storage and reading scope. This does not mean zero effect, no papers or failed access.
Review incomplete: Review of existing content or actual review incomplete.
Not reported: Used only when original materials were actually read and the outcome was judged unreported. Not used for external materials unread in this work.
Inaccessible: Used only when an actual access attempt has a recorded failure. Not used for access that was not attempted in this work.
Insufficient evidence for the conditions: Indicates insufficient direct materials for the relevant scope or conditions; it is not a new grade.
Not applicable: Used when the reason it does not apply to the original question is stated.
Conflicting data: Retains the scope of conflicting statements in original materials; it is not an arbitrary reassessment.

Change history

2026-10-12 · Public page/material version 1.0

Public reader pages and materials were prepared from the existing 39 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What is the original direction of the selected existing question?

Current findings: The selected question is “No QTc or blood-pressure effect” in the existing subclaim, distinguished from its verdict record. The original no-problem claim wording is retained, separately from the original context that harm signals did not support it.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new independent-claim certification, invented verdict or subclaim subdivision was made.
Reason for missing information: No new independent-claim certification, invented verdict or subclaim subdivision was made.
Required materials and conditions: Exact subclaim wording, Korean/English text and question/record relationship
Materials to obtain first: Selected existing verdict record and complete parent summary
Further research: If the question changes, retain the original existing wording, previous complete version and change event separately.
Remaining uncertainty: Preparation scope of the stored summary. No new independent-claim certification, invented verdict or subclaim subdivision was made.
Conditions for verification: Connect Exact subclaim wording, Korean/English text and question/record relationship to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Exact subclaim wording, Korean/English text and question/record relationship.
Application exceptions: Do not count trials, participants or clinical events twice because two existing checklists were prepared.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are our own design

Related sources R01

N02 · How do the subclaim verdict and parent score/axes differ?

Current findings: The subclaim is D, with the note “QTc and blood-pressure trajectories differed from placebo.” It has no score/status/axes fields. Parent D30, Caution and B/S/R1/I2/E-/B2/C0 are parent context.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Subclaim score/status/assessment axes are null; parent values are not inserted.
Reason for missing information: Subclaim score/status/assessment axes are null; parent values are not inserted.
Required materials and conditions: Actual subclaim grade/note, absent score/status/axes and parent D30
Materials to obtain first: Original subclaim record and parent grade/score/axes and assessment history
Further research: When evidence is updated, distinguish original value preservation from actual judgment events.
Remaining uncertainty: Preparation scope of the stored summary. Subclaim score/status/assessment axes are null; parent values are not inserted.
Conditions for verification: Connect Actual subclaim grade/note, absent score/status/axes and parent D30 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Actual subclaim grade/note, absent score/status/axes and parent D30.
Application exceptions: Do not inherit parent D30 or historical cross-checks as a subclaim score, current content-review pass or new independence certification.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources R01

N03 · What are the actual trial population and applicability boundaries?

Current findings: The 2019 trial involved 34 healthy adults aged 18–40 without cardiovascular disease, hypertension, QT prolongation or regular medication use.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.
Reason for missing information: Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.
Required materials and conditions: Healthy adults aged 18–40, baseline exclusions and selected population
Materials to obtain first: Recruitment/baseline characteristics, eligibility and outcome-specific flow
Further research: Distinguish other population materials by baseline risk, medication, age and actual eligibility.
Remaining uncertainty: Preparation scope of the stored summary. Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.
Conditions for verification: Connect Healthy adults aged 18–40, baseline exclusions and selected population to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Healthy adults aged 18–40, baseline exclusions and selected population.
Application exceptions: Do not extend the healthy young population to adolescents, patients, regular medication users or all consumers.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

Related sources R01

N04 · What are the actual identity and duration of the research exposure?

Current findings: The original exposure was a single intake of 946 mL of energy drink containing about 300–320 mg caffeine within one hour.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.
Reason for missing information: Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.
Required materials and conditions: 946 mL, about 300–320 mg caffeine and one exposure within one hour
Materials to obtain first: Product composition, actual exposure, intake completion and crossover records
Further research: Connect nominal/actual and product-specific exposure differences with the relevant outcome.
Remaining uncertainty: Preparation scope of the stored summary. Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.
Conditions for verification: Connect 946 mL, about 300–320 mg caffeine and one exposure within one hour to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 946 mL, about 300–320 mg caffeine and one exposure within one hour.
Application exceptions: Do not calculate or create can counts, caffeine equivalents, safe limits or intake/manufacturing/dosing guidance.
Referenced methods: M03 §3.2.2–3.2.3; reverse labeling and test adaptations are Chamgap's own design

Related sources R01

N05 · What are the identity and composition differences of drinks A/B and placebo?

Current findings: The stored review summary records investigators preparing commercial drinks in identical containers and participants consuming A, B and placebo separately.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.
Reason for missing information: Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.
Required materials and conditions: Commercial products A/B, preparation in identical containers and placebo composition
Materials to obtain first: Trial product/placebo composition, preparation and distinguishability
Further research: If actual product materials are provided, distinguish caffeine, combined ingredients and placebo differences.
Remaining uncertainty: Preparation scope of the stored summary. Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.
Conditions for verification: Connect Commercial products A/B, preparation in identical containers and placebo composition to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Commercial products A/B, preparation in identical containers and placebo composition.
Application exceptions: Do not use the 2017 caffeine-comparison title to verify that the 2019 placebo was caffeine-matched.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

Related sources R01

N06 · How do 240-minute measurements differ from long-term observation?

Current findings: The 2019 trial measured QTc and blood pressure every 30 minutes through 240 minutes after a single exposure.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.
Reason for missing information: Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.
Required materials and conditions: Measurements through 240 minutes, 30-minute intervals and acute time points
Materials to obtain first: Visit/washout schedule, outcome collection and event follow-up scope
Further research: Distinguish actual observation durations of acute biomarkers and long-term clinical outcomes in follow-up materials.
Remaining uncertainty: Preparation scope of the stored summary. Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.
Conditions for verification: Connect Measurements through 240 minutes, 30-minute intervals and acute time points to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Measurements through 240 minutes, 30-minute intervals and acute time points.
Application exceptions: Do not convert four hours into sufficient clinical-event testing duration or long-term safety.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; Design-specific harm questions in M19 §19.2; Detailed temporal relationships are internally designed

Related sources R01

N07 · What are the sequence and analysis units of the crossover trial?

Current findings: The recorded design is a randomized double-masked placebo-controlled crossover trial; the same participants underwent each drink condition.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.
Reason for missing information: Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.
Required materials and conditions: A/B/placebo in the same 34 people, sequence allocation and carryover/period effects
Materials to obtain first: Crossover flow, sequence/period and original analysis model
Further research: When materials are supplemented, distinguish conditions/time points within the same person and crossover assumptions.
Remaining uncertainty: Preparation scope of the stored summary. Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.
Conditions for verification: Connect A/B/placebo in the same 34 people, sequence allocation and carryover/period effects to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of A/B/placebo in the same 34 people, sequence allocation and carryover/period effects.
Application exceptions: Do not sum A/B/placebo, repeated time points or two checklists as independent participants/trials.
Referenced methods: M08 §8.1–8.2.3; CHAMGAP adaptation; Distinction between studies and reports in M04 §4.6.1–4.6.2; Cohort/outcome connections are CHAMGAP adaptations

Related sources R01

N08 · What are the common conditions and other exposures?

Current findings: The stored review summary preserves a healthy population and acute comparison of three drinks.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.
Reason for missing information: Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.
Required materials and conditions: Pre-visit caffeine/activity, meals, medication and measurement environment
Materials to obtain first: Pre-visit conditions, concurrent exposure and actual implementation/measurement records
Further research: Record actual common product-comparison conditions and other exposures together in follow-up materials.
Remaining uncertainty: Preparation scope of the stored summary. Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.
Conditions for verification: Connect Pre-visit caffeine/activity, meals, medication and measurement environment to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Pre-visit caffeine/activity, meals, medication and measurement environment.
Application exceptions: Do not invent fasting/rest/restriction times or experimental/daily-life procedures absent from the stored review summary.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; Chamgap adaptation

Related sources R01

N09 · How were double masking, measurement and interpretation implemented?

Current findings: The original design is described as double-masked, with investigators preparing drinks in identical containers.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.
Reason for missing information: Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.
Required materials and conditions: Roles masked, identical containers and ECG/blood-pressure collection
Materials to obtain first: Masking, measurement/interpretation methods and original collection materials
Further research: Connect actual masking by role and measurement processes to outcomes.
Remaining uncertainty: Preparation scope of the stored summary. Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.
Conditions for verification: Connect Roles masked, identical containers and ECG/blood-pressure collection to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Roles masked, identical containers and ECG/blood-pressure collection.
Application exceptions: Do not newly verify masking of all interpretations or absence of measurement errors solely from identical containers or a design label.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources R01

N10 · What are the registration identifier and current registration-content status?

Current findings: NCT03196908 appears in the first existing evidence record and research description. The 2017 citation has no separate registration identifier.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.
Reason for missing information: Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.
Required materials and conditions: 2019 NCT03196908 and registration history/plans
Materials to obtain first: Original 2019 registration/plans and separate 2017 registration/method materials
Further research: If registration materials are provided, distinguish the report, plans and actual reading scope.
Remaining uncertainty: Preparation scope of the stored summary. Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.
Conditions for verification: Connect 2019 NCT03196908 and registration history/plans to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2019 NCT03196908 and registration history/plans.
Application exceptions: Do not copy the 2019 NCT as the 2017 registration identifier or upgrade identifier presence to registration verification/link checks.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a and M04 §4.6.3; Chamgap application

Related sources R01 R02

N11 · What are the bibliographies and source locations of the two reports?

Current findings: R01 is Shah SA et al., 2019, J Am Heart Assoc 8:e011318, PMID 31137991. R02 is Fletcher EA et al., 2017, the same journal 6:e004448, PMID 28446495. There is one evidence group and two citations.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.
Reason for missing information: DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.
Required materials and conditions: Shah 2019, Fletcher 2017, PMIDs and evidence/citations
Materials to obtain first: Original bibliography, full text and registration/population connections for each report
Further research: When bibliography is supplemented, distinguish report identity, original results and change events.
Remaining uncertainty: Preparation scope of the stored summary. DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.
Conditions for verification: Connect Shah 2019, Fletcher 2017, PMIDs and evidence/citations to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Shah 2019, Fletcher 2017, PMIDs and evidence/citations.
Application exceptions: Do not create an evidence group absent from the stored summary for R02 or infer DOI/PMCID from article numbers.
Referenced methods: M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

Related sources R01 R02

N12 · What is the scope of investigator overlap and Mayo blood-pressure replication?

Current findings: The stored review summary states that 2017 involved overlapping investigators and was not independent replication; independent Mayo investigators replicated blood pressure only. Limited independent QTc replication is a historical description.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.
Reason for missing information: Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.
Required materials and conditions: Identical/unknown cohorts, author overlap and independent QTc/BP distinction
Materials to obtain first: Authors/institutions, registration, participant families and actual Mayo reports
Further research: Distinguish identical cohorts, investigator overlap, independent institutions and QTc/blood-pressure endpoint replication in new materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.
Conditions for verification: Connect Identical/unknown cohorts, author overlap and independent QTc/BP distinction to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Identical/unknown cohorts, author overlap and independent QTc/BP distinction.
Application exceptions: Do not equate investigator overlap with an identical cohort or create R03/independent clinical-arrhythmia evidence from unspecified Mayo mentions.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources R01 R02

N13 · What is the original scope of support and disclosed relationships?

Current findings: The original record states University of the Pacific support, no reported energy-drink-company funding and Sachin A. Shah’s expert-witness history in caffeine energy-drink litigation.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.
Reason for missing information: Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.
Required materials and conditions: 2019 university support, unreported company funding and litigation expert-witness history
Materials to obtain first: Original support, product provision, author disclosures and analysis/publication roles for each report
Further research: If disclosures are provided, distinguish reports, support types, external relationships and historical/current scope.
Remaining uncertainty: Preparation scope of the stored summary. Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.
Conditions for verification: Connect 2019 university support, unreported company funding and litigation expert-witness history to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2019 university support, unreported company funding and litigation expert-witness history.
Application exceptions: Do not upgrade university support or unreported company funding to new independence certification, absence of conflicts or identical 2017 support.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources R01 R02

N14 · How are original dates, Korean/English text, corrections, axes and history retained?

Current findings: The reference date is 2026-08-26, corrections are an empty array and deliberation an empty string. Complete stored review text preserves Korean/English content, synthesized summaries, verdict decisions, assessment axes and false flags.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.
Reason for missing information: Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.
Required materials and conditions: 2026-08-26, empty corrections/deliberation and parent/sibling context
Materials to obtain first: Complete original stored review summary and actual correction/change events
Further research: If changed materials arise, distinguish the complete pre-change original, events, versions and separate application.
Remaining uncertainty: Preparation scope of the stored summary. Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.
Conditions for verification: Connect 2026-08-26, empty corrections/deliberation and parent/sibling context to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2026-08-26, empty corrections/deliberation and parent/sibling context.
Application exceptions: Do not fill original grades, absences, empty values or historical cross-checks with new values/current completed review.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

Related sources R01 R02

N15 · Which materials were actually read?

Current findings: The complete preserved 2961 JSON and its two existing selections were read for preparation. Reading of each report’s summary is distinguished from unread external originals in each checklist.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.
Reason for missing information: External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.
Required materials and conditions: Complete local JSON summary, report-specific material items and unread external originals
Materials to obtain first: User-provided original materials and actual acquisition/reading records
Further research: Distinguish public availability, access, acquisition, actual reading scope and dates for new materials.
Remaining uncertainty: Preparation scope of the stored summary. External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.
Conditions for verification: Connect Complete local JSON summary, report-specific material items and unread external originals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Complete local JSON summary, report-specific material items and unread external originals.
Application exceptions: Do not convert original citation links, historical paper descriptions or copies into external full-text reading/successful access.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources R01 R02

N16 · Are two checklists/material items distinguished from trials/participants?

Current findings: The two existing questions have different scopes in the same complete stored summary. Connecting R01’s 34 people, A/B/placebo and time-point materials to both checklists creates no new participant or replication trial.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.
Reason for missing information: Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.
Required materials and conditions: s0/s1, two reports, conditions/time points and null unique trial/participant totals
Materials to obtain first: Trial-report-participant-condition-time-point-question relationships
Further research: Connect additional reports by distinguishing identical/different populations, institutions and endpoints.
Remaining uncertainty: Preparation scope of the stored summary. Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.
Conditions for verification: Connect s0/s1, two reports, conditions/time points and null unique trial/participant totals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of s0/s1, two reports, conditions/time points and null unique trial/participant totals.
Application exceptions: Do not add two checklists/reports/crossover conditions or 34-person values to create an independent total sample.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; design-specific adaptation is Chamgap’s own design

Related sources R01 R02

N17 · What is connected when new materials become available?

Current findings: The two existing questions are prepared separately in the same seven-column format. Each condition was saved/frozen first, with a separate application timestamp retained.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.
Reason for missing information: No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.
Required materials and conditions: Conditions, originals, observations, corrections, reading and change events
Materials to obtain first: User-provided direct endpoint/denominator/plan, clinical event, correction and harm materials
Further research: Separate actual additions/changes into complete prior originals, events, condition versions/freezing, separate application and current handoff.
Remaining uncertainty: Preparation scope of the stored summary. No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.
Conditions for verification: Connect Conditions, originals, observations, corrections, reading and change events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Conditions, originals, observations, corrections, reading and change events.
Application exceptions: Original candidate pending/eligibility indications are historical; do not reactivate them as active review/waiting.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

Related sources R01 R02

N18 · What are the QTc correction methods and actual endpoints?

Current findings: The existing evidence endpoint is Bazett- and Fridericia-corrected QTc; the numeric table concerns maximum Bazett-QTc change. QTc is an ECG marker of delayed ventricular repolarization.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Correction formulas, original QT/RR, equipment/interpretation, Fridericia values and actual maximum derivation are unverified.
Reason for missing information: Correction formulas, original QT/RR, equipment/interpretation, Fridericia values and actual maximum derivation are unverified.
Required materials and conditions: Bazett/Fridericia, maximum change and QTc definition
Materials to obtain first: Original ECG results/measurement and maximum derivation by correction method
Further research: If materials are provided, connect correction methods, original values/changes, time points and maxima separately.
Remaining uncertainty: Preparation scope of the stored summary. Correction formulas, original QT/RR, equipment/interpretation, Fridericia values and actual maximum derivation are unverified.
Conditions for verification: Connect Bazett/Fridericia, maximum change and QTc definition to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Bazett/Fridericia, maximum change and QTc definition.
Application exceptions: Do not transfer Bazett values to Fridericia or clinical-arrhythmia outcomes.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

Related sources R01

N19 · How are original maximum Bazett-QTc values retained?

Current findings: Maximum Bazett-QTc changes are A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms. Each is recorded as a maximum change from baseline.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. The statistical definition of ±, condition-specific n, maximum time points, baseline values and original change variance tables are unverified.
Reason for missing information: The statistical definition of ±, condition-specific n, maximum time points, baseline values and original change variance tables are unverified.
Required materials and conditions: A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms
Materials to obtain first: Condition-specific maxima/time points, baseline, variance and denominator result tables
Further research: Connect condition-specific values and actual statistical definitions in new tables.
Remaining uncertainty: Preparation scope of the stored summary. The statistical definition of ±, condition-specific n, maximum time points, baseline values and original change variance tables are unverified.
Conditions for verification: Connect A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of A +17.9±13.9 ms, B +19.6±15.8 ms and placebo +11.9±11.1 ms.
Application exceptions: Do not call these original values between-group differences or subtract placebo values to calculate new effects/CIs.
Referenced methods: M03 §3.2.4 and M15 §§15.3.1–15.3.3; question-specific outcome adaptation is Chamgap-designed; M04 §4.6.3 and M15 §§15.3.1–15.3.3; status separation is Chamgap-designed

Related sources R01

N20 · What are the actual comparisons in overall and pairwise tests?

Current findings: The original reader answer records overall P=.005, A versus placebo P=.04 and B versus placebo P<.01; both drinks had larger maximum QTc changes than placebo.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Test models, multiplicity corrections, estimated between-condition differences and paired analysis details are unverified.
Reason for missing information: Test models, multiplicity corrections, estimated between-condition differences and paired analysis details are unverified.
Required materials and conditions: Overall P=.005, A versus placebo P=.04 and B versus placebo P<.01
Materials to obtain first: Original tests/contrasts, multiplicity and between-condition estimates
Further research: Connect overall, pairwise and adjusted tests with the relevant outcomes in analysis materials.
Remaining uncertainty: Preparation scope of the stored summary. Test models, multiplicity corrections, estimated between-condition differences and paired analysis details are unverified.
Conditions for verification: Connect Overall P=.005, A versus placebo P=.04 and B versus placebo P<.01 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Overall P=.005, A versus placebo P=.04 and B versus placebo P<.01.
Application exceptions: Do not convert pairwise P values into a direct A/B superiority or clinical-risk ranking.
Referenced methods: M08 §8.2.2, M15 §15.3.1; CHAMGAP adaptation; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP

Related sources R01

N21 · How do QTc-by-time results differ from maximum-change tests?

Current findings: QTc-by-time interaction P<.001 and overall maximum Bazett-QTc test P=.005 are separate results in the original stored review summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Correction-specific time models, between-condition effects/intervals at each time point and measurement denominators are unverified.
Reason for missing information: Correction-specific time models, between-condition effects/intervals at each time point and measurement denominators are unverified.
Required materials and conditions: Time interaction P<.001 and overall maximum P=.005
Materials to obtain first: Time models, QTc by time point, maxima and result tables
Further research: When materials are supplemented, distinguish time interactions from contrasts of a single summary value.
Remaining uncertainty: Preparation scope of the stored summary. Correction-specific time models, between-condition effects/intervals at each time point and measurement denominators are unverified.
Conditions for verification: Connect Time interaction P<.001 and overall maximum P=.005 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Time interaction P<.001 and overall maximum P=.005.
Application exceptions: Do not convert time-interaction P values into effects at particular time points, individual conditions or clinical events.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

Related sources R01

N22 · Which sites and pressure types do blood-pressure results concern?

Current findings: The original research description states that peripheral and central systolic- and diastolic-pressure-by-time interactions were all P<.001.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Absolute values, changes, between-group differences, mmHg intervals and visit-specific measurement/denominators for each pressure are absent from the stored review summary.
Reason for missing information: Absolute values, changes, between-group differences, mmHg intervals and visit-specific measurement/denominators for each pressure are absent from the stored review summary.
Required materials and conditions: Peripheral/central, systolic/diastolic and time interactions
Materials to obtain first: Original pressure values, changes, time points, equipment/conditions and result tables
Further research: Distinguish sites, pressure types, time points and within-/between-condition results in new blood-pressure materials.
Remaining uncertainty: Preparation scope of the stored summary. Absolute values, changes, between-group differences, mmHg intervals and visit-specific measurement/denominators for each pressure are absent from the stored review summary.
Conditions for verification: Connect Peripheral/central, systolic/diastolic and time interactions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Peripheral/central, systolic/diastolic and time interactions.
Application exceptions: Do not create new values/conclusions for blood-pressure magnitude, hypertension diagnosis, sustained increases or clinical events.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

Related sources R01

N23 · What is the scope of unreported between-condition 95% CIs?

Current findings: Original research text and synthesized summaries record that the paper did not present between-condition 95% CIs. External originals/supplementary tables were not read this time.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual intervals/non-reporting across current external materials and effect denominators are unverified.
Reason for missing information: Actual intervals/non-reporting across current external materials and effect denominators are unverified.
Required materials and conditions: Between-condition intervals, ± notation, P values and original non-reporting record
Materials to obtain first: Original between-condition estimates/CIs, denominators and supplements
Further research: Connect provided intervals with actual correction methods, measures and denominators.
Remaining uncertainty: Preparation scope of the stored summary. Actual intervals/non-reporting across current external materials and effect denominators are unverified.
Conditions for verification: Connect Between-condition intervals, ± notation, P values and original non-reporting record to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Between-condition intervals, ± notation, P values and original non-reporting record.
Application exceptions: Do not convert ± into CIs or calculate between-condition CIs/effects from P values or sample size.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design

Related sources R01

N24 · What kind of threshold is 10 ms?

Current findings: Sample size assumed detection of a 10-ms QTc mean difference. The stored review summary states that without a CI for a between-condition difference exceeding 10 ms, this was not used to exclude a clinical threshold.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Validated clinical importance, the relevant between-condition interval and prespecified criterion details are unverified.
Reason for missing information: Validated clinical importance, the relevant between-condition interval and prespecified criterion details are unverified.
Required materials and conditions: Power assumption of a 10-ms QTc mean difference and clinical interpretation boundary
Materials to obtain first: Original power, clinical importance and between-condition estimate materials
Further research: If materials are provided, connect sample-size assumptions and validated clinical thresholds separately.
Remaining uncertainty: Preparation scope of the stored summary. Validated clinical importance, the relevant between-condition interval and prespecified criterion details are unverified.
Conditions for verification: Connect Power assumption of a 10-ms QTc mean difference and clinical interpretation boundary to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Power assumption of a 10-ms QTc mean difference and clinical interpretation boundary.
Application exceptions: Do not newly confirm a between-condition threshold or arrhythmia risk because each condition’s maximum change exceeds 10 ms.
Referenced methods: M15 §§15.3.1–15.3.3; Chamgap adaptation

Related sources R01

N25 · What are the 34-person sample, actual outcome analysis and missingness?

Current findings: The stored review summary’s n is 34 healthy adults. Details are insufficient to establish 34 effective measurements/analyses in every crossover condition/time point.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Allocation/exposure/condition completion, effective ECG/blood-pressure n, missingness reasons/handling and analysis populations/models are unverified.
Reason for missing information: Allocation/exposure/condition completion, effective ECG/blood-pressure n, missingness reasons/handling and analysis populations/models are unverified.
Required materials and conditions: 34 study participants, effective n by condition/time, completion and ITT/paired analysis
Materials to obtain first: Crossover/outcome-specific flow, denominators and missingness/analysis records
Further research: If original tables are provided, distinguish person, condition, time-point and outcome denominators.
Remaining uncertainty: Preparation scope of the stored summary. Allocation/exposure/condition completion, effective ECG/blood-pressure n, missingness reasons/handling and analysis populations/models are unverified.
Conditions for verification: Connect 34 study participants, effective n by condition/time, completion and ITT/paired analysis to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 34 study participants, effective n by condition/time, completion and ITT/paired analysis.
Application exceptions: Do not copy 34 as a verified analysis denominator at each time point or multiply it by observations.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources R01

N26 · What are the prespecified primary QTc and blood-pressure hierarchy?

Current findings: The stored review summary records worsening of prespecified primary QTc. Blood-pressure time interactions are also recorded, but separate hierarchy/plan details are absent.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Original registration/SAP QTc definitions, correction methods, maximum/time analyses, primary/secondary blood pressure and multiple testing are unverified.
Reason for missing information: Original registration/SAP QTc definitions, correction methods, maximum/time analyses, primary/secondary blood pressure and multiple testing are unverified.
Required materials and conditions: Prespecified QTc, correction/maxima/time analyses and blood-pressure hierarchy
Materials to obtain first: Prespecified protocols/SAPs, registration histories and endpoint/analysis hierarchy
Further research: If plans are provided, connect actual prespecified/post hoc distinctions, endpoint hierarchy and selected analyses.
Remaining uncertainty: Preparation scope of the stored summary. Original registration/SAP QTc definitions, correction methods, maximum/time analyses, primary/secondary blood pressure and multiple testing are unverified.
Conditions for verification: Connect Prespecified QTc, correction/maxima/time analyses and blood-pressure hierarchy to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Prespecified QTc, correction/maxima/time analyses and blood-pressure hierarchy.
Application exceptions: Do not upgrade parent assessment axes or historical stored descriptions to current plan-review certification.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

Related sources R01

N27 · How are the no-problem claim and original observed direction distinguished?

Current findings: The exact question is “No QTc or blood-pressure effect.” The stored review summary records that QTc/blood-pressure trajectory differences from placebo did not support the claim.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Clinical importance of measured differences and applicability to persistence/long-term/all exposures are unverified.
Reason for missing information: Clinical importance of measured differences and applicability to persistence/long-term/all exposures are unverified.
Required materials and conditions: No-effect claim, QTc/blood-pressure changes and original D/note
Materials to obtain first: Original selected-claim wording and direct endpoint/clinical importance materials
Further research: Connect original claim, observed direction and verdict context as recorded; distinguish separate actual clinical outcomes.
Remaining uncertainty: Preparation scope of the stored summary. Clinical importance of measured differences and applicability to persistence/long-term/all exposures are unverified.
Conditions for verification: Connect No-effect claim, QTc/blood-pressure changes and original D/note to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of No-effect claim, QTc/blood-pressure changes and original D/note.
Application exceptions: Do not reverse the original claim into confirmed increased clinical arrhythmia or make a new assessment.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; Status distinctions are designed by CHAMGAP; Question clarification principles in M03 §3.1 and §3.2.1–3.2.4; Detailed separation rules are internally designed

Related sources R01

N28 · What is the boundary between surrogate markers and clinical events?

Current findings: The stored review summary explicitly states that this is a four-hour biomarker trial that did not test arrhythmia, hospitalization or death. The sibling s1 grade is ?.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct clinical event definitions, event counts, denominators, durations and effect intervals are unverified in these materials.
Reason for missing information: Direct clinical event definitions, event counts, denominators, durations and effect intervals are unverified in these materials.
Required materials and conditions: QTc/blood-pressure surrogate signals and direct arrhythmia/hospitalization/death outcomes
Materials to obtain first: Direct clinical-event follow-up/comparisons and diagnostic/occurrence materials
Further research: Retain a proposal to report clinical-event materials with definitions, verification, risk periods and denominators separate from biomarkers.
Remaining uncertainty: Preparation scope of the stored summary. Direct clinical event definitions, event counts, denominators, durations and effect intervals are unverified in these materials.
Conditions for verification: Connect QTc/blood-pressure surrogate signals and direct arrhythmia/hospitalization/death outcomes to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of QTc/blood-pressure surrogate signals and direct arrhythmia/hospitalization/death outcomes.
Application exceptions: Do not transfer QTc prolongation/blood-pressure differences to occurrence effects for clinical arrhythmia, hospitalization or death.
Referenced methods: M03 §3.2.4; internally defined extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

Related sources R01

N29 · Is this extended to other doses, chronic use or populations?

Current findings: The stored review summary states that results cannot be extended to chronic intake, one can or less, adolescents, cardiovascular patients or medication users.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct QTc/blood-pressure/clinical-event materials for other products/doses, repeated exposure and at-risk populations are unverified.
Reason for missing information: Direct QTc/blood-pressure/clinical-event materials for other products/doses, repeated exposure and at-risk populations are unverified.
Required materials and conditions: Healthy adults aged 18–40, a single high-volume exposure and direct evidence for other conditions
Materials to obtain first: Direct outcomes for each actual exposure, population and duration
Further research: If direct materials are provided, distinguish exposure/population/duration differences for the relevant question.
Remaining uncertainty: Preparation scope of the stored summary. Direct QTc/blood-pressure/clinical-event materials for other products/doses, repeated exposure and at-risk populations are unverified.
Conditions for verification: Connect Healthy adults aged 18–40, a single high-volume exposure and direct evidence for other conditions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Healthy adults aged 18–40, a single high-volume exposure and direct evidence for other conditions.
Application exceptions: Do not create small-dose safety, chronic harms, general-population intake limits or dosing/care guidance.
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

Related sources R01

N30 · What is the scope of the earlier 2017 report and Mayo blood-pressure context?

Current findings: Fletcher 2017 has a bibliography for an energy-drink-versus-caffeine ECG/hemodynamic trial and a summary of QTc prolongation direction. Independent Mayo blood-pressure descriptions are historical context without a bibliography.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual 2017 effects/CIs/sample, Mayo bibliography/conditions/values and direct independent QTc verification are unverified.
Reason for missing information: Actual 2017 effects/CIs/sample, Mayo bibliography/conditions/values and direct independent QTc verification are unverified.
Required materials and conditions: Overlapping-investigator QTc direction and independent blood-pressure-only description
Materials to obtain first: Actual original outcomes and population/institution/registration connections for each report
Further research: Distinguish institution/population relationships and actual replicated endpoints in additional report materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual 2017 effects/CIs/sample, Mayo bibliography/conditions/values and direct independent QTc verification are unverified.
Conditions for verification: Connect Overlapping-investigator QTc direction and independent blood-pressure-only description to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Overlapping-investigator QTc direction and independent blood-pressure-only description.
Application exceptions: Do not copy 2019 values, n or NCT to 2017/Mayo or convert the description into independent clinical-event replication.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; Status distinctions are designed by CHAMGAP; M04 §4.6.1–4.6.2, M15 §15.3.1; CHAMGAP adaptation

Related sources R01 R02

H01 · Are biomarkers, harms and clinical-event collection distinguished?

Current findings: Original materials record QTc/BP time changes and no testing of arrhythmia/hospitalization/death. The original context is that biomarker differences did not support the selected no-problem claim.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.
Reason for missing information: Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.
Required materials and conditions: QTc/BP testing, verified clinical events and adverse-event definitions
Materials to obtain first: Collection plans, harm definitions and direct clinical outcome tables
Further research: Retain a proposal to distinguish measured biomarkers, symptoms and verified events in follow-up materials.
Remaining uncertainty: Preparation scope of the stored summary. Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.
Conditions for verification: Connect QTc/BP testing, verified clinical events and adverse-event definitions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of QTc/BP testing, verified clinical events and adverse-event definitions.
Application exceptions: Do not convert biomarker worsening into clinical-event counts or untested outcomes into zero adverse events.
Referenced methods: M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

Related sources R01

H02 · What are harm timing and actual exposure?

Current findings: Research exposure was 946 mL with about 300–320 mg caffeine within one hour; measurements covered 240 minutes.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.
Reason for missing information: Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.
Required materials and conditions: Single research exposure, acute measurement and event-risk periods
Materials to obtain first: Actual exposure, response times and event follow-up/risk windows
Further research: Retain a proposal to distinguish exposure, testing times and clinical-event risk periods in harm materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.
Conditions for verification: Connect Single research exposure, acute measurement and event-risk periods to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Single research exposure, acute measurement and event-risk periods.
Application exceptions: Do not convert the original exposure into recommended intake, a safe dose or prevention/treatment methods.
Referenced methods: M19 §19.2 design-specific harm questions; timing details are Chamgap-designed

Related sources R01

H03 · How do between-condition biomarker differences differ from clinical harm comparisons?

Current findings: The stored review summary records maximum QTc and blood-pressure time differences, while direct clinical arrhythmia/hospitalization/death comparisons were not tested.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.
Reason for missing information: Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.
Required materials and conditions: Biomarker outcomes for A/B/placebo and clinical-event comparisons
Materials to obtain first: Actual clinical-event comparators, counts and estimates
Further research: Retain a proposal to connect direct harm materials using event definitions, comparisons and intervals separate from biomarkers.
Remaining uncertainty: Preparation scope of the stored summary. Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.
Conditions for verification: Connect Biomarker outcomes for A/B/placebo and clinical-event comparisons to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker outcomes for A/B/placebo and clinical-event comparisons.
Application exceptions: Do not transfer biomarker P values to clinical-harm P values or between-condition event risks.
Referenced methods: M19 §§19.2.2–19.2.4 and M03 §3.2.3; Chamgap adaptation

Related sources R01

H04 · What are safety and event denominators?

Current findings: The 34 people in the stored review summary are healthy adult crossover-trial participants; separate denominators for each event/safety analysis were not provided.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.
Reason for missing information: Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.
Required materials and conditions: 34 people and actual denominators by condition/time/event
Materials to obtain first: Safety/event denominators, condition-specific flow and original counts
Further research: Retain a proposal to distinguish person, condition, time-point and measurement/event denominators in originals.
Remaining uncertainty: Preparation scope of the stored summary. Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.
Conditions for verification: Connect 34 people and actual denominators by condition/time/event to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 34 people and actual denominators by condition/time/event.
Application exceptions: Do not multiply crossover conditions/time measurements into participant counts or calculate risk rates from unread materials.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3 and M19 §§19.1.2–19.2.4; design-specific adaptation is Chamgap-designed

Related sources R01

H05 · What are alternative harm factors and ingredient-specific attribution?

Current findings: Exposure was commercial energy drink with about 300–320 mg caffeine. The stored review summary preserves a whole-product comparison.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.
Reason for missing information: Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.
Required materials and conditions: Caffeine, combined ingredients, baseline/concurrent exposures and relatedness
Materials to obtain first: Original ingredients, concurrent exposures, baseline risk and harm-case assessment
Further research: Retain a proposal to distinguish whole products, ingredient-specific attribution and alternative factors in direct harm materials.
Remaining uncertainty: Preparation scope of the stored summary. Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.
Conditions for verification: Connect Caffeine, combined ingredients, baseline/concurrent exposures and relatedness to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Caffeine, combined ingredients, baseline/concurrent exposures and relatedness.
Application exceptions: Do not attribute every signal to caffeine alone or established harm from a particular ingredient, or invent mechanisms/event cases.
Referenced methods: M19 §§19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap-designed

Related sources R01

H06 · Are unread, untested, unreported and zero events distinguished?

Current findings: Actual reading this time concerns preserved JSON summaries; the original description of untested clinical events is retained.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.
Reason for missing information: Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.
Required materials and conditions: Actual reading level, untested clinical endpoints and original reports
Materials to obtain first: Original collection plans, complete results, missingness reasons and reading records
Further research: Only for provided materials, connect actual zero events, missingness, non-reporting and non-collection with locations/durations.
Remaining uncertainty: Preparation scope of the stored summary. Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.
Conditions for verification: Connect Actual reading level, untested clinical endpoints and original reports to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Actual reading level, untested clinical endpoints and original reports.
Application exceptions: Do not convert currently unread materials into zero side effects, failed access, an absent paper or confirmed direct clinical harm.
Referenced methods: M19 §§19.1.2–19.2.4 and M04 §4.6.3; Chamgap adaptation

Related sources R01 R02

H07 · Are harms across reports, conditions and two checklists protected from duplicate counting?

Current findings: Two checklists prepare different existing questions from the same stored 2961 summary. The 2017/2019 bibliographies involve overlapping investigators; actual participant overlap is unverified.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.
Reason for missing information: Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.
Required materials and conditions: 2017/2019, author overlap, conditions/time points and two questions in the same summary
Materials to obtain first: Report-person-condition-time-point-event-question relationships
Further research: Retain a proposal to distinguish repeated reports of the same event from different populations/new events in harm materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.
Conditions for verification: Connect 2017/2019, author overlap, conditions/time points and two questions in the same summary to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2017/2019, author overlap, conditions/time points and two questions in the same summary.
Application exceptions: Do not equate investigator overlap with the same cohort or count two bibliographies/checklists as new independent-event replication.
Referenced methods: M04 §§4.6.1–4.6.2; harm-material adaptation is Chamgap-designed; M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

Related sources R01 R02

H08 · What are safety gaps for long-term use and vulnerable populations?

Current findings: The parent emphasizes a single high-volume exposure in healthy young adults; the original safety status is Caution.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.
Reason for missing information: Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.
Required materials and conditions: Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents
Materials to obtain first: Direct harms and clinical follow-up by exposure/duration/risk population
Further research: Retain a proposal to record direct materials together with actual exposure, population and observation duration.
Remaining uncertainty: Preparation scope of the stored summary. Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.
Conditions for verification: Connect Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents.
Application exceptions: Do not create safe-dose, intake/care, arrhythmia prevention/treatment or medical-replacement procedures.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation

Related sources R01

H09 · Are signals distinguished from direct causal or clinical confirmation?

Current findings: Original s0 is D for the no-QTc/BP-effect claim; s1 is ? for increased clinical arrhythmia. Biomarker signals and the gap in direct clinical events are retained separately.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.
Reason for missing information: No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.
Required materials and conditions: Biomarker signals, original D, direct clinical ? and unverified information
Materials to obtain first: Actual biomarker/clinical-event materials, denominators, intervals and verification
Further research: Retain a proposal to distinguish observation, relatedness, direct clinical-effect levels and change events in additional materials.
Remaining uncertainty: Preparation scope of the stored summary. No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.
Conditions for verification: Connect Biomarker signals, original D, direct clinical ? and unverified information to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker signals, original D, direct clinical ? and unverified information.
Application exceptions: Do not label original question wording as proven observation or combine biomarkers and clinical events into a new harm assessment.
Referenced methods: Chamgap interpretive boundary informed by M19 principles; no formal causality tool was run

Related sources R01